Autotelic Lab to present at AACC 2012
Autotelic Lab will be presenting data on its platform of expanded range point-of-care diagnostic devices
By: Autotelic Lab
IVF Protocols—with a target of generating between 8 and 15 oocytes—are complex, time consuming, expensive and may give rise to considerable patient discomfort and increased chance of complications, especially the Ovarian Hyperstimulation Syndrome (OHSS) and possible long term side effects such as increased cancer risk. Ovarian epithelial cancer is more common in individuals with elevated Gonadotropin-
Herein, Dr. Kouros Motamed and colleagues describe the development of rapid point-of-care tests for detection of FSH using the expanded range platform alleviating the needs for complicated dilutions and repeats making it truly a point-of-care test. Traditional immunoassay for FSH exhibits at best two logs of dynamic range (1-100 IU/L); whereas, our FSH assay exhibits at least 4 logs of dynamic range (1-10,000 IU/L). As such, these tests would allow for more effective screening for ovarian cancer as well as therapeutic drug monitoring of FSH. These findings will be presented at American Association for Clinical Chemistry Annual Meeting (AACC), July 15-19th, 2012, Los Angeles, CA, USA.
Abstract # D-70: Expanded Range Point-of-Care Therapeutic Drug Monitoring (TDM
assay for FSH. Kouros Motamed, Larn Hwang, Chao Hsiao, Vuong Trieu. Tuesday, July 17, 2:00 pm – 4:30 pm Point-of-Care Testing.
AACC is an international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry and related disciplines. Founded in 1948, the society has over 8,000 members and is headquartered in Washington, DC. AACC vision is to provide leadership in advancing the practice and profession of clinical laboratory science and its application to health care. AACC annual meeting is the world's largest lab medicine conference with nearly 20,000 participants from more than 100 countries.
About Autotelic Lab:
Autotelic lab is a provider of quantitative point-of-care testing solutions including quantitative lateral flow cassettes, lateral flow reader, as well as a quantification service. Our product lines include emergency care, women's health, cancer biomarkers, and regenerative medicine. Our offerings are uniquely configured to accept multiple readers to satisfy all possible field conditions; from highly specialized requiring specificity and sensitivity to low tech without access to normal laboratory resources. Our mission is to put testing into the hands of primary care providers and patients. These tests are simple to use and require no specialized equipment or trained personnel. They are rapid with results within 20 minutes of blood collection. They are convenient and can be deployed at home, in doctor’s office, in emergency rooms, or in centralized laboratories. Moreover, they are quantitative with a linear response range similar to tests performed at centralized laboratories.
These proprietary diagnostic devices deployed at point-of-care are being used for therapeutic drug monitoring by our partner―Biomiga Diagnostics―
The executives of Autotelic Lab are a group of pharmaceutical veterans who believe that the next revolution in medicine is in point-of-care tests for optimal drug dosing. With more than a decade of drug development experience, the leadership team has expertise ranging from basic/applied research, preclinical/
Kouros Motamed, Ph.D.
Chief Executive Officer